CD102 (ICAM-2) Monoclonal Antibody (CBR-IC2/2), FITC, eBioscience™, Invitrogen™

Description

• Description: The CBRIC2/2 monoclonal antibody reacts with human ICAM-2 (CD102)
• ICAM-2 is a 55-65 kD transmembrane glycoprotein possessing 2 extracellular Ig domains, a single transmembrane domain, and a short 26-amino acid cytoplasmic domain
• ICAM-2 is expressed on most leukocytes, and is strongly expressed on vascular endothelial cells
• ICAM-2 is a ligand of integrin CD11a/CD18 (LFA-1), and also has been reported to bind integrin CD11b/CD18 (Mac-1)
• ICAM-2 is an intercellular adhesion molecule involved in lymphocyte homing to sites of inflammation
• The CBRIC2/2 antibody has been reported to have blocking activity
• Applications Reported: This CBRIC2/2 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This CBRIC2/2 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at 5 μL (0.5 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser
• Filtration: 0.2 μm post-manufacturing filtered
• ICAM-2 is a member of the intercellular adhesion molecule (ICAM) family
• All ICAM proteins are type I transmembrane glycoproteins, contain 2-9 immunoglobulin-like C2-type domains, and bind to the leukocyte adhesion LFA-1 protein
• ICAM-2 may play a role in lymphocyte recirculation by blocking LFA-1-dependent cell adhesion
• It mediates adhesive interactions important for antigen-specific immune response, NK-cell mediated clearance, lymphocyte recirculation, and other cellular interactions important for immune response and surveillance
• Several transcript variants encoding the same protein have been found for this gene
• Diseases associated with ICAM2 include Colon Carcinoma In Situ.